Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.57 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.17NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.1.8NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.1.10NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.3.3 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.28.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.7.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.4.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.65NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.39.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.4.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.7.6NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.3.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.15NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.3.6NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EU.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.2.3.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.59NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.24.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.17.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.63NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GW.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DZ.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DZ.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DY.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.12NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.7.14.6NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.119.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.121 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.14 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.119 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.46.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.114 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.54 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.64 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.46.4 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.107 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.81 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.117 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.118 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.27 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.617.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.67 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.110 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.39.1 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.20 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used